Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies. This evidence concerns the gene RPS6 and chronic myelogenous leukemia, BCR-ABL1 positive.